BRIEF: Hutchmed profit falls on shrinking R&D income
Hutchmed (China) Ltd. (HCM.US; 0013.HK; HCM.L), a biopharmaceutical company controlled by CK Hutchison Holdings (0001.HK), said its revenue fell 24.8% last year to $630 million, according to its annual results…
NEWS WRAP: Hutchmed sells non-core asset to focus on cancer treatment
The drug maker is selling most of its stake in a joint venture with Shanghai Pharmaceuticals for $608 million By Teri Yu Hutchmed (China) Ltd. (HCM.US; 0013.HK; HCM.L), the biopharmaceutical…
BRIEF: Ascentage Pharma gets Chinese regulatory nod for U.S. listing
Biopharmaceutical company Ascentage Pharma Group International (6855.HK) received a listing approval notice from the China Securities Regulatory Commission (CSRC) on Monday, a necessary step before it can make an overseas…
Hutchmed scores U.S. success with cancer drug, but profits still dip
The drug developer has reported sharply reduced profits, coming off an exceptionally high base last year, but sales of its key cancer medicine are accelerating in the United States Key…
FAST NEWS: Hutchmed Sells Cancer Drug’s Overseas Rights for up to $1.13 Billion
The latest: Hutchmed (China) Ltd. (HCM.US; 0013.HK) announced on Wednesday that it has exclusively licensed Japan’s Takeda Pharmaceutical (TAK.US; 4502.T) to develop, manufacture and sell its metastatic colorectal cancer drug…
Recent Articles
RELATED ARTICLES
-
NEWS WRAP: Hutchmed sells non-core asset to focus on cancer treatment
0013.HK HCM.US
-
Inmagene Bio charts backdoor to U.S. listing with offshore acquisition
IKNA.US
-
Growing profits, shrinking market share test ZTO’s strategy
2507.HK ZTO.US
-
BRIEF: Huya’s revenue, profit fall as user base keeps shrinking
HUYA.US
-
BRIEF: Ascentage Pharma gets Chinese regulatory nod for U.S. listing
6855.HK
-
BRIEF: Giordano’s profit falls 30% in 2024
0709.HK
-
BRIEF: SMIC’s fourth-quarter revenue jumps, but profit falls
0981.HK 688981.SHG
